Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Talen Energy Corp V.TLN


Primary Symbol: TLN

Talen Energy Corporation owns and operates power infrastructure in the United States. The Company produces and sells electricity, capacity, and ancillary services in wholesale power markets in the United States, primarily in PJM and WECC, with its generation fleet principally located in the Mid-Atlantic region of the United States and Montana. The majority of its generation is produced at its zero-carbon nuclear and lower-carbon gas-fired facilities. Its generation capacity is 10,665 megawatts (MW). Its segments include PJM and Other. The PJM segment is engaged in electricity generation, marketing activities, commodity risk and fuel management within the PJM RTO or ISO markets and comprises Susquehanna and Talen’s natural gas and coal generation facilities. Its Other segment includes the operating and marketing activities of Talen Montana’s proportionate share of the Colstrip Units in the WECC market, the operating activities of Nautilus, and other development activities.


NDAQ:TLN - Post by User

Bullboard Posts
Post by Everswanon Apr 21, 2009 8:15pm
126 Views
Post# 15934731

Raf-1 inhibition and RAS-GTP level

Raf-1 inhibition and RAS-GTP level
https://en.wikipedia.org/wiki/C-Raf


check out image
https://en.wikipedia.org/wiki/File:RAF.png


We are now closer than ever to finally reveilling 4601 mecanism of action - "RAS-GTP decrease". That finding would be a major breakthrough in cancer research.

4601 is basically bypassing every mutation known to block efficacy for other drugs.

https://www.thallion.com/docs/publications/26.AACR09-Batist-Web.pdf



These posters won't ring a bell for the common market player but for oncologist, this is certainly very interesting to note:

TLN-4601 potentiates both erlotinib and gefitinib in non-small cell
lung cancer cell lines harboring sensitive or resistant TKI EGFr
mutations
TNL-4601 in combination with TKIs overcomes the T790M-TKI
Exponentially growing cells were seeded in 96-well plates at a resistant mutation (NCI-H1975)
TLN-4601 enhances erlotinib and gefitinib activity irregardless of
EGFr expression or mutation status
TLN-4601 demonstrates strong synergistic activity with erlotinib,
and to a lesser extent with gefitinib, in K-Ras mutated cells


Very nice scientific finding.


It's time to negociate how much u want to pay for TLN!
I say 4$ per share and there will be no shareholder revolt.
Cheap price tag at 120 Millions, very cheap.

(or) 200 millions licensing deal with upfront payment of 10M.

(or) white knight intervention and pumping of 30M cash infusion. Yup that's all 30M and TLN could go it alone and get accelerated market approval.







Bullboard Posts

USER FEEDBACK SURVEY ×

Be the voice that helps shape the content on site!

At Stockhouse, we’re committed to delivering content that matters to you. Your insights are key in shaping our strategy. Take a few minutes to share your feedback and help influence what you see on our site!

The Market Online in partnership with Stockhouse